Click here to close now.


News Feed Item

Sanofi Launches MyStar Extra®, the First Blood Glucose Monitoring Device to Support Insulin Therapy Management With Estimated HbA1c

GUILDFORD, England, March 20, 2014 /PRNewswire/ --

- Discover how smart technologies can help people with diabetes better understand their insulin therapy and health improvements -

MyStarExtra®, a new generation blood glucose monitoring device developed by Sanofi, is now available in the United Kingdom. MyStar Extra® is the first self-monitoring device that provides estimates of the HbA1c value, a key indicator for long-term glucose control.[i],[ii] This unique blood glucose monitoring device may help people with diabetes better understand the meaning of their test results in the context of overall treatment goals. Several extra features of the device may help people with diabetes stay motivated and engaged in managing their insulin therapy.

"Living with Type 1 diabetes is hard work with no time off. It's a constant balancing act between ensuring I have the correct amounts of insulin to keep my blood glucose at safe levels. This takes motivation. For me to stay motivated in my diabetes management I need accurate and consistent data from my blood glucose device. Without this, I am unable to make the informed decisions that I need to manage my diabetes the way that I want to. Next to insulin, reliable data from my blood glucose device is the most important tool that I have to manage my diabetes. I welcome any new technologies that may support me stay motivated and engaged" said Chris Aldred, @grumpy_pumper,

MyStar  Extra®  provides  key  benefits  to  support  patients  manage  their  insulin  therapy

The new MyStar Extra® blood glucose device from Sanofi provides relevant blood glucose information and comes with new features. It can help keep patients motivated to take an active role in managing their insulin therapy.[iii] One of the parameters used to assess the level of glycaemic control in people with diabetes is the HbA1c (haemoglobin A1c) value. The HbA1c value reflects average glucose levels over the previous three months and is therefore regarded as an indicator for long term glucose control.[v],[vi] Until now, HbA1c levels were obtained through a laboratory test which patients receive on average once or twice a year, but now MyStar Extra® can provide an HbA1c estimate. The device uses unique algorithms to provide estimates of HbA1c. While this does not replace the laboratory test, it provides more immediate feedback on therapy progress.[iv],[vii]

In addition to the HbA1c estimate, MyStar Extra® calculates a three-day fasting plasma glucose average (FPG) and FPG trends. For people with diabetes who find it challenging to follow treatment regimes, three-day fasting averages simplify access to practical glucose information. FPG values measure the blood glucose concentration in a blood sample after an overnight fast. Three-day FPG averages are commonly used to titrate basal insulin, one of the most used treatment approaches in type 2 diabetes.[viii] The innovative technology of MyStar Extra®, simplifies diabetes management through using smart technology to produce immediate feedback.

"We are delighted that MyStar Extra® will now be available for people with diabetes in the United Kingdom. Sanofi has developed MyStar Extra® with the needs of people using or starting on insulin in mind. The device provides the personal glucose information people with diabetes need in a simple form, enabling them to manage their diabetes and track their long-term therapy success. This is what smart technology is all about: MyStar Extra® helps patients understand control of their diabetes better, and helps to motivate them to stick to their recommended therapy", said Becky Reeve, Head of Professional Relations, Sanofi UK.

MyStar Extra® and the new lancing device MyStar SylkFeel® will be available in the United Kingdom from March 2014. They will complement the MyStar® portfolio of Sanofi, combining devices, services and guidance for simple and effective diabetes management.

About  diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycaemia). Over time, uncontrolled hyperglycaemia leads to macro vascular and micro vascular complications of diabetes. Macro vascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Micro vascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate.

A blood glucose monitoring device reads the amount of sugar released in the blood, which has previously been absorbed from food or built up by the body. The glucose value is measured with a small sample of blood, usually taken from a finger and then applied to a disposable test strip. Based on blood glucose readings, many people with diabetes have to adjust their medication or insulin doses to keep the amount of glucose in the blood to target levels.

About  Sanofi  Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

About  Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking  Statements

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


i. Fisher WA et al. What Primary Care Providers Can Do to Address Barriers to Self-Monitoring of Blood Glucose. Clinical Diabetes 2013;31(1):34-42.

ii. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998; 352: 837-53.

iii Delamater A, et al. Improving patient adherence. Clinical Diabetes April 2006;24 (2): 71-77.

iv MyStar Extra™ Blood Glucose Monitoring System Owner's Guide.

v Clinical Guideline Task Force, Global Guidelines for Type 2 diabetes, International Diabetes Federation, 2005. Available at: Accessed July 2013.

vi World Health Organization, Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus, 2011. Available at: Accessed July 2013.

vii Cagliero E, et al. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999;22:1785-1789.

viii Strange et al. J Diabetes Sci Technol 2007;1(4):540-548.

ix Kovatchev BP, et al. Effect of automated bio-behavioral feedback on the control of type 1 diabetes. Diabetes Care. 2011 Feb; 34 (2):302-7. Epub 2011 Jan 7.

x Breton M. Robustness of dynamical real-time estimation of A1C using routine self-monitoring of blood glucose (SMBG) data Abstr 1079 EASD 2013

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As operational failure becomes more acceptable to discuss within the software industry, the necessity for holding constructive, actionable postmortems increases. But most of what we know about postmortems from "pop culture" isn't actually relevant for the software systems we work on and within. In his session at DevOps Summit, J. Paul Reed will look at postmortem pitfalls, techniques, and tools you'll be able to take back to your own environment so they will be able to lay the foundations for h...
Nowadays, a large number of sensors and devices are connected to the network. Leading-edge IoT technologies integrate various types of sensor data to create a new value for several business decision scenarios. The transparent cloud is a model of a new IoT emergence service platform. Many service providers store and access various types of sensor data in order to create and find out new business values by integrating such data.
There are so many tools and techniques for data analytics that even for a data scientist the choices, possible systems, and even the types of data can be daunting. In his session at @ThingsExpo, Chris Harrold, Global CTO for Big Data Solutions for EMC Corporation, will show how to perform a simple, but meaningful analysis of social sentiment data using freely available tools that take only minutes to download and install. Participants will get the download information, scripts, and complete en...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at @DevOpsSummit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
Containers are all the rage among developers and web companies, but they also represent two very substantial benefits to larger organizations. First, they have the potential to dramatically accelerate the application lifecycle from software builds and testing to deployment and upgrades. Second they represent the first truly hybrid-approach to consuming infrastructure, allowing organizations to run the same workloads on any cloud, virtual machine or physical server. Together, they represent a ver...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in high-performance, high-efficiency server, storage technology and green computing, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology is a premier provider of advanced server Building Block Solutions® for Data ...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Achim Weiss is Chief Executive Officer and co-founder of ProfitBricks. In 1995, he broke off his studies to co-found the web hosting company "Schlund+Partner." The company "Schlund+Partner" later became the 1&1 web hosting product line. From 1995 to 2008, he was the technical director for several important projects: the largest web hosting platform in the world, the second largest DSL platform, a video on-demand delivery network, the largest eMail backend in Europe, and a universal billing syste...
Between the compelling mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how busine...
Interested in leveraging automation technologies and a cloud architecture to make developers more productive? Learn how PaaS can benefit your organization to help you streamline your application development, allow you to use existing infrastructure and improve operational efficiencies. Begin charting your path to PaaS with OpenShift Enterprise.
IT data is typically silo'd by the various tools in place. Unifying all the log, metric and event data in one analytics platform stops finger pointing and provides the end-to-end correlation. Logs, metrics and custom event data can be joined to tell the holistic story of your software and operations. For example, users can correlate code deploys to system performance to application error codes.
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, will introduce the technologies required for implementing thes...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, will review the current landscape of...